YL-13027 is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to GlobalData, Phase I drugs for Metastatic Adenocarcinoma of The Pancreas have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how YL-13027’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

YL-13027 overview

YL-13027 is under development for the treatment of advanced solid tumors including gastrointestinal tract cancer, metastatic pancreatic adenocarcinoma, esophageal cancer, gallbladder cancer, lung cancer, head and neck cancer, renal clear cell carcinoma, urinary epithelial carcinoma (transitional cell carcinoma (urothelial cell carcinoma)), chordoma, glioma, meningioma, ependymoma, craniopharyngioma and refractory pituitary tumor and breast cancer. The drug candidate acts by targeting beta isoform of transforming growth factor (TGF-beta). The drug candidate is administered by oral route of administration. It was also under development for multiple myeloma and myelodysplastic syndrome.

Shanghai Yingli Pharmaceutical overview

Shanghai Yingli Pharmaceutical (Yingli) is a pharmaceutical company focused on discovery and development of innovative small molecule drugs for the treatment of cancer, autoimmune diseases, and metabolic disorders. Yingli is headquartered in Shanghai, China.

For a complete picture of YL-13027’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.